Submitted by Leidos
Leidos and the Milken Institute Center for Public Health (CPH) recently published a new report highlighting the work done by both organizations to address the addiction and mental health crises that deepened during the COVID-19 pandemic.
Why you should know: While COVID-19 itself claimed millions of lives, the pandemic also increased demand for the treatment for addiction, anxiety and depression. Data from the U.S. Centers for Disease Control and Prevention shows that drug overdose deaths reached record levels in 2021, and suicide rates were back near a record high after two years of decline.
In 2021, Leidos and the Milken Institute formed the CEO Collaborative Action Group to mobilize employers across industries to join the cause. More than 85 organizations joined the CEO Collaborative Action Group, representing an estimated 3 million employees nationwide.
What the results show:
From the source: “This all started with an email from a grieving father,” said Roger Krone, Leidos Chairman and CEO. “We cannot ignore the real, but often silent, challenges facing our employees. By bringing together such a diverse group of employers, we’re being a catalyst for change. This is important work and I’m proud of what we’ve accomplished."
You can view a full copy of the report here.
Leidos is a Fortune 500® technology, engineering, and science solutions and services leader working to solve the world's toughest challenges in the defense, intelligence, civil, and health markets. The company's 44,000 employees support vital missions for government and commercial customers. Headquartered in Reston, Va., Leidos reported annual revenues of approximately $13.7 billion for the fiscal year ended December 31, 2021. For more information, visit www.Leidos.com.
More from Leidos